Vivesto AB (OASMY)

Market Cap	6.15M -45.6%
Revenue (ttm)	n/a
Net Income	-3.79M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	0.00 (676.00%)
Ex-Dividend Date	Jan 28, 2026

Volume	1,000
Average Volume	2,235
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	0.0001 - 0.0200
Beta	1.04
RSI	36.25
Earnings Date	Feb 26, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: OASMY

Financial Performance

Financial numbers in SEK